ÂÜÀòÂÒÂ×

Cecilia Kemi is an experienced professional in the fields of clinical operations and medical research, currently serving as Chief Operating Officer at Attgeno AB since April 2021 and as a pre-clinical and clinical consultant at Kemista AB since August 2019. Kemi has held positions such as Chief Operating Officer at QuiaPEG AB and Nordic Phase IV Manager at Novartis, where responsibilities included overseeing local phase IV studies, vendor management, and cross-departmental coordination. Previous roles also include Director of Clinical Bioanalysis at Bionor Pharma and Project Coordinator/Post Doc at Karolinska Institutet, contributing to pre-clinical studies and coordination of clinical development programs. Kemi holds a PhD in Lung Medicine and Allergology from Karolinska Institutet and a Master's degree in Molecular Biology from Umeå University.